Publications by authors named "K Himuro"

Article Synopsis
  • Dysphagia, a common symptom in patients with myasthenia gravis (MG), is linked to muscle weakness and a lack of coordination in swallowing and breathing.
  • The study recorded breathing patterns and muscle activity during swallowing in 10 MG patients and 22 healthy controls, finding significant differences in their respiratory patterns.
  • These findings suggest that monitoring breathing and muscle activity can effectively indicate the severity of swallowing difficulties in MG patients, particularly after treatment.
View Article and Find Full Text PDF
Article Synopsis
  • Myasthenia gravis (MG) is an autoimmune disorder that affects muscle communication, and researchers are exploring the potential of pentraxin 3 (PTX3) as a biological marker for disease activity.
  • Serum PTX3 levels were measured in both MG patients and healthy controls, with findings indicating that while there wasn't a significant difference in PTX3 levels between the groups, PTX3 did correlate moderately with various MG severity scores.
  • The study suggests that PTX3 could be a relevant indicator of neuromuscular junction damage in MG patients, potentially aiding in understanding the disease's progression.
View Article and Find Full Text PDF

Objective: To examine the impact of acquisition time on Lutetium-177 (Lu) single-photon emission computed tomography (SPECT) images using Monte Carlo simulation.

Methods: A gamma camera simulation based on the Monte Carlo method was performed to produce SPECT images. The phantom was modeled on a NEMA IEC BODY phantom including six spheres as tumors.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated how quickly patients with AChR antibody-positive generalized myasthenia gravis (MG) could achieve a treatment status called "minimal manifestation" (MM) and the factors affecting this.
  • A retrospective analysis was conducted on 93 patients over 3 years, tracking symptoms, treatment, and the achievement of MM.
  • About 60% of patients reached MM status by 3 months and 90% by 2 years, with more frequent plasmapheresis and higher doses of prednisolone making it harder to achieve a lower dosage goal by 2 years.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how changes in anti-acetylcholine receptor antibody (AChR Ab) levels after immunosuppressive treatment relate to the long-term prognosis of myasthenia gravis (MG) patients one year later.
  • Researchers analyzed 53 AChR Ab-positive MG patients, measuring their antibody levels again within 100 days of starting treatment to assess the reduction rate of these antibodies.
  • Results showed that patients with a higher reduction rate of AChR Ab were more likely to achieve a better clinical status and had lower MG-related activity scores after one year, indicating that early antibody level measurements can help predict treatment outcomes.
View Article and Find Full Text PDF